Literature DB >> 28522318

Survival of women with microinvasive adenocarcinoma of the cervix is not improved by radical surgery.

Lisa M Bean1, Kristy K Ward2, Steven C Plaxe3, Michael T McHale3.   

Abstract

BACKGROUND: Treatment for early-invasive adenocarcinoma of the cervix remains controversial. Although data have shown similar survival rates to those seen with squamous cell carcinoma, conservative options for patients with microinvasive adenocarcinoma have not been as widely accepted. Despite comparable survival outcomes, patients with early-invasive adenocarcinoma are still routinely subjected to more radical surgical techniques than their equivalently staged squamous cell counterparts.
OBJECTIVE: The objective of the study was to evaluate how less radical surgery has an impact on 5 year survival in patients with microinvasive adenocarcinoma of the cervix. STUDY
DESIGN: The Surveillance, Epidemiology, and End Results database was queried from 1988 through 2010 to perform a retrospective analysis of women with International Federation of Gynecology and Obstetrics stage IA1 or IA2 cervical carcinoma. Five year survival by procedure type (local excision, simple hysterectomy, or radical hysterectomy) was determined for each cell type (squamous or adenocarcinoma), as was lymph node status.
RESULTS: Among 1567 patients with cervical adenocarcinoma, 5 year survival was 97.3% (confidence interval, 95.8-98.2%) for stage IA1 disease and 98.3% (confidence interval, 96.5%, 99.2%) for stage IA2. For comparison, the 5-year survival rates for 5,749 patients with stage IAI or lA2 squamous cell carcinoma were 96.7% (confidence interval, 96.0-97.3%) and 95.6% (confidence interval, 94.4-96.5%), respectively. For stage IA1 ACA, survival was 96.6%, 98.4% and 96.5% following excision, hysterectomy and radical hysterectomy, respectively. For stage IA2 ACA, survival rates were 100%, 96.9% and 99.4%, respectively. There was no statistical difference in survival between patients having either cell type undergoing local excision (P = .26), simple hysterectomy (P = .08), or radical hysterectomy (P = .87). We also found no statistically significant difference in survival among patients with adenocarcinoma compared by treatment type (local excision compared with simple hysterectomy [P = .64]; local excision compared with radical hysterectomy [P = .82]; or simple hysterectomy compared with radical hysterectomy [P = .70]). Among patients with adenocarcinoma, 0.97% had positive pelvic lymph nodes, none had positive aortic lymph nodes, and 91.85% had confirmed negative lymph nodes. For squamous cell carcinoma, 0.72% of patients had positive pelvic lymph nodes and 0.10% had positive aortic lymph nodes.
CONCLUSION: There was no significant difference in survival when patients were compared by cell type or procedure, suggesting that survival of patients with microinvasive adenocarcinoma is not improved by utilizing more invasive surgical methods. Regardless of histology, the frequency of nodal involvement was very low among both groups, supporting an overall excellent prognosis for all patients with microinvasive disease. We submit these data as evidence that preoperative planning of more conservative techniques is appropriate, not just for those with squamous histology or who desire future fertility, but for all patients with microinvasive cervical disease.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  adenocarcinoma; cervical cancer; cervix; lymph node dissection; lymphadenectomy; microinvasive; squamous cell carcinoma; survival

Mesh:

Year:  2017        PMID: 28522318     DOI: 10.1016/j.ajog.2017.05.021

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  7 in total

1.  Clinical Epidemiology of Microinvasive Cervical Carcinoma in an Italian Population Targeted by a Screening Programme.

Authors:  Lauro Bucchi; Silvano Costa; Silvia Mancini; Flavia Baldacchini; Orietta Giuliani; Alessandra Ravaioli; Rosa Vattiato; Federica Zamagni; Paolo Giorgi Rossi; Cinzia Campari; Debora Canuti; Priscilla Sassoli de Bianchi; Stefano Ferretti; Fabio Falcini
Journal:  Cancers (Basel)       Date:  2022-04-22       Impact factor: 6.575

2.  The Prostaglandin EP3 Receptor Is an Independent Negative Prognostic Factor for Cervical Cancer Patients.

Authors:  Helene Heidegger; Sebastian Dietlmeier; Yao Ye; Christina Kuhn; Aurelia Vattai; Caroline Aberl; Udo Jeschke; Sven Mahner; Bernd Kost
Journal:  Int J Mol Sci       Date:  2017-07-19       Impact factor: 5.923

Review 3.  Diagnosis and Management of Adenocarcinoma in Situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations.

Authors:  Deanna Teoh; Fernanda Musa; Ritu Salani; Warner Huh; Edward Jimenez
Journal:  Obstet Gynecol       Date:  2020-04       Impact factor: 7.623

4.  A case of extremely early cervical adenocarcinoma diagnosed only by endocervical curettage with macroscopic pelvic lymph node metastases.

Authors:  Jae Hak Jung; Byoung Ryun Kim
Journal:  Obstet Gynecol Sci       Date:  2019-10-24

5.  Clinicopathological characteristics and prognostic factors of cervical adenocarcinoma.

Authors:  Min Wang; Bo Yuan; Zhen-Huan Zhou; Wei-Wei Han
Journal:  Sci Rep       Date:  2021-04-05       Impact factor: 4.379

6.  Oncologic and obstetric outcomes after conization for adenocarcinoma in situ or stage IA1 cervical cancer.

Authors:  Xiaoyu Wang; Yalan Bi; Huanwen Wu; Ming Wu; Lei Li
Journal:  Sci Rep       Date:  2020-11-16       Impact factor: 4.379

7.  Adenosquamous Carcinoma of the Cervix: A Population-Based Analysis.

Authors:  Pengfei Cui; Xiaofeng Cong; Chen Chen; Lei Yang; Ziling Liu
Journal:  Front Oncol       Date:  2021-07-22       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.